Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines

Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains

We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Fixing essential medicine shortages: obstacles and opportunities

Global health experts and governing bodies agree that everyone has a right to access the medicines they need. The COVID-19 pandemic and resulting drug shortages have underscored the critical need to protect this right…
Transforming Medicinal Supply Chains

In the Future of Everything radio show, Stanford bioengineers Russ Altman and Christina Smolke discuss advances in synthetic biology and the rise of opioids made from yeast.